365 related articles for article (PubMed ID: 23863692)
1. Posttranslational modification of the androgen receptor in prostate cancer.
van der Steen T; Tindall DJ; Huang H
Int J Mol Sci; 2013 Jul; 14(7):14833-59. PubMed ID: 23863692
[TBL] [Abstract][Full Text] [Related]
2. Posttranslational regulation of androgen dependent and independent androgen receptor activities in prostate cancer.
Wen S; Niu Y; Huang H
Asian J Urol; 2020 Jul; 7(3):203-218. PubMed ID: 33024699
[TBL] [Abstract][Full Text] [Related]
3. Regulating Androgen Receptor Function in Prostate Cancer: Exploring the Diversity of Post-Translational Modifications.
Lumahan LEV; Arif M; Whitener AE; Yi P
Cells; 2024 Jan; 13(2):. PubMed ID: 38275816
[TBL] [Abstract][Full Text] [Related]
4. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
[TBL] [Abstract][Full Text] [Related]
5. Post-translational modification of the androgen receptor.
Gioeli D; Paschal BM
Mol Cell Endocrinol; 2012 Apr; 352(1-2):70-8. PubMed ID: 21820033
[TBL] [Abstract][Full Text] [Related]
6. Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer.
Kobayashi T; Inoue T; Kamba T; Ogawa O
Int J Mol Sci; 2013 Jul; 14(8):15615-35. PubMed ID: 23896594
[TBL] [Abstract][Full Text] [Related]
7. FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants.
Bohrer LR; Liu P; Zhong J; Pan Y; Angstman J; Brand LJ; Dehm SM; Huang H
Prostate; 2013 Jul; 73(10):1017-27. PubMed ID: 23389878
[TBL] [Abstract][Full Text] [Related]
8. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
Watson PA; Chen YF; Balbas MD; Wongvipat J; Socci ND; Viale A; Kim K; Sawyers CL
Proc Natl Acad Sci U S A; 2010 Sep; 107(39):16759-65. PubMed ID: 20823238
[TBL] [Abstract][Full Text] [Related]
9. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
Hörnberg E; Ylitalo EB; Crnalic S; Antti H; Stattin P; Widmark A; Bergh A; Wikström P
PLoS One; 2011 Apr; 6(4):e19059. PubMed ID: 21552559
[TBL] [Abstract][Full Text] [Related]
10. ARD1/NAA10 acetylation in prostate cancer.
Kuhns KJ; Zhang G; Wang Z; Liu W
Exp Mol Med; 2018 Jul; 50(7):1-8. PubMed ID: 30054487
[TBL] [Abstract][Full Text] [Related]
11. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.
Chen L; Siddiqui S; Bose S; Mooso B; Asuncion A; Bedolla RG; Vinall R; Tepper CG; Gandour-Edwards R; Shi X; Lu XH; Siddiqui J; Chinnaiyan AM; Mehra R; Devere White RW; Carraway KL; Ghosh PM
Cancer Res; 2010 Jul; 70(14):5994-6003. PubMed ID: 20587519
[TBL] [Abstract][Full Text] [Related]
12. Angiogenin mediates androgen-stimulated prostate cancer growth and enables castration resistance.
Li S; Hu MG; Sun Y; Yoshioka N; Ibaragi S; Sheng J; Sun G; Kishimoto K; Hu GF
Mol Cancer Res; 2013 Oct; 11(10):1203-14. PubMed ID: 23851444
[TBL] [Abstract][Full Text] [Related]
13. Determinants of Gli2 co-activation of wildtype and naturally truncated androgen receptors.
Li N; Chen M; Truong S; Yan C; Buttyan R
Prostate; 2014 Oct; 74(14):1400-10. PubMed ID: 25132524
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal.
Chan SC; Li Y; Dehm SM
J Biol Chem; 2012 Jun; 287(23):19736-49. PubMed ID: 22532567
[TBL] [Abstract][Full Text] [Related]
15. Androgen ablation elicits PP1-dependence for AR stabilization and transactivation in prostate cancer.
Liu X; Han W; Gulla S; Simon NI; Gao Y; Liu J; Wang L; Yang H; Zhang X; Chen S
Prostate; 2016 May; 76(7):649-61. PubMed ID: 26847655
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the androgen receptor by post-translational modifications.
Coffey K; Robson CN
J Endocrinol; 2012 Nov; 215(2):221-37. PubMed ID: 22872761
[TBL] [Abstract][Full Text] [Related]
17. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
Peacock SO; Fahrenholtz CD; Burnstein KL
Mol Endocrinol; 2012 Dec; 26(12):1967-79. PubMed ID: 23023561
[TBL] [Abstract][Full Text] [Related]
18. Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells.
Dehm SM; Regan KM; Schmidt LJ; Tindall DJ
Cancer Res; 2007 Oct; 67(20):10067-77. PubMed ID: 17942941
[TBL] [Abstract][Full Text] [Related]
19. Post-translational modifications of nuclear receptors and human disease.
Anbalagan M; Huderson B; Murphy L; Rowan BG
Nucl Recept Signal; 2012; 10():e001. PubMed ID: 22438791
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor gene rearrangements: new perspectives on prostate cancer progression.
Brand LJ; Dehm SM
Curr Drug Targets; 2013 Apr; 14(4):441-9. PubMed ID: 23410127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
